Guidelines for ATC classification and DDD assignment - WHOCC

More documents

Recommendations

Info

P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS P01 ANTIPROTOZOALS A Agents against amoebiasis and other protozoal diseases B Antimalarials C Agents against leishmaniasis and trypanosomiasis P02 ANTHELMINTICS B Antitrematodals C Antinematodal agents D Anticestodals P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS A Ectoparasiticides, incl. scabicides B Insecticides and repellents 225
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 226 The group is subdivided according to types of parasites. P01 ANTIPROTOZOALS P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES This group comprises drugs mainly used for amoeba infections and other protozoal diseases such as giardiasis and trichomoniasis. P01AA Hydroxyquinoline derivatives All combined preparations containing clioquinol are classified in this group. Formulations of chlorquinaldol and clioquinol for dermatological use are classified in D08AH. No DDDs are established in this group. P01AB Nitroimidazole derivatives Nitroimidazole derivatives used for amoebiasis, trichomoniasis and giardiasis are classified in this group. Formulations for vaginal administration are classified in G01AF. Parenteral formulations mainly used for treatment of anaerobic bacterial infections are classified in J01XD. Fixed combination packages for eradication of Helicobacter pylori are classified in A02BD. The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis. The duration of the treatment periods is not taken into consideration. P01AC Dichloroacetamide derivatives This group comprises luminal amoebicides.
Page 1 and 2:
2011 WHO Collaborating Centre for D
Page 3 and 4:
ISSN 1726-4898 ISBN 978-82-8082-438
Page 5 and 6:
Previous editions: 1990: Guidelines
Page 7 and 8:
Staff of the Centre Christian Berg,
Page 9 and 10:
8 D. Principles for reviewing and c
Page 11 and 12:
I. INTRODUCTION A. History of the A
Page 13 and 14:
- To organize training courses in t
Page 15 and 16:
It is open to anyone with a legitim
Page 17 and 18:
B. Inclusion and exclusion criteria
Page 19 and 20:
If a new substance fits in both a c
Page 21 and 22:
Example: N02BA71 - acetylsalicylic
Page 23 and 24:
achieved. The harmonisation process
Page 25 and 26:
- For some groups of medicinal prod
Page 27 and 28:
For all combination products where
Page 29 and 30:
- Liquid preparations for inhalatio
Page 31 and 32:
Further reviews of DDDs After the f
Page 33 and 34:
linked to each medicinal product on
Page 35 and 36:
Use of the ATC/DDD system allows st
Page 37 and 38:
The WHO Collaborating Centre for In
Page 39 and 40:
It should be emphasised that assign
Page 41 and 42:
- If no objections are received, th
Page 43 and 44:
In order to include proposals for A
Page 45 and 46:
considered as a guideline since the
Page 47 and 48:
List of DDDs for combined products
Page 49 and 50:
ATC SYSTEM MAIN GROUPS The main gro
Page 51 and 52:
A08 ANTIOBESITY PREPARATIONS, EXCL.
Page 53 and 54:
A01AC Corticosteroids for local ora
Page 55 and 56:
A02AF Antacids with antiflatulents
Page 57 and 58:
56 combination will, together with
Page 59 and 60:
58 The classification at the 5th le
Page 61 and 62:
A03EA Antispasmodics, psycholeptics
Page 63 and 64:
A06 LAXATIVES A06A LAXATIVES 62 Lax
Page 65 and 66:
A06AG Enemas 64 All enemas and laxa
Page 67 and 68:
A07C ELECTROLYTES WITH CARBOHYDRATE
Page 69 and 70:
A08 ANTIOBESITY PREPARATIONS, EXCL.
Page 71 and 72:
A10B BLOOD GLUCOSE LOWERING DRUGS,
Page 73 and 74:
72 In A11AA04 only trace elements a
Page 75 and 76:
74 The DDDs are based on prophylaxi
Page 77 and 78:
76 classified in this group. Even c
Page 79 and 80:
78 Tonics are classified in A13. Th
Page 81 and 82:
A12CC Magnesium A12CD Fluoride A12C
Page 83 and 84:
A16 OTHER ALIMENTARY TRACT AND META
Page 85 and 86:
B BLOOD AND BLOOD FORMING ORGANS B0
Page 87 and 88:
B02 ANTIHEMORRHAGICS B02A ANTIFIBRI
Page 89 and 90:
B03AA Iron bivalent, oral preparati
Page 91 and 92:
90 The DDDs are based on maintenanc
Page 93 and 94:
B05C IRRIGATING SOLUTIONS 92 In thi
Page 96 and 97:
C CARDIOVASCULAR SYSTEM C01 CARDIAC
Page 98 and 99:
C CARDIOVASCULAR SYSTEM C01 CARDIAC
Page 100 and 101:
C01C CARDIAC STIMULANTS EXCL. CARDI
Page 102 and 103:
C01E OTHER CARDIAC PREPARATIONS Thi
Page 104 and 105:
Combinations with other antihyperte
Page 106 and 107:
C02DD Nitroferricyanide derivatives
Page 108 and 109:
C02LX Other antihypertensives and d
Page 110 and 111:
C03BX Other low-ceiling diuretics A
Page 112 and 113:
C04AC Nicotinic acid and derivative
Page 114 and 115:
C05BA Heparins or heparinoids for t
Page 116 and 117:
C07BG Alpha and beta blocking agent
Page 118 and 119:
Combinations with ACE inhibitors ar
Page 120 and 121:
C09BB ACE inhibitors and calcium ch
Page 122:
C10B LIPID MODIFYING AGENTS, COMBIN
Page 125 and 126:
D10 ANTI-ACNE PREPARATIONS A Anti-a
Page 127 and 128:
D01AC Imidazole and triazole deriva
Page 129 and 130:
D02B PROTECTIVES AGAINST UV-RADIATI
Page 131 and 132:
D04AX Other antipruritics 130 This
Page 133 and 134:
D06AX Other antibiotics for topical
Page 135 and 136:
D07BB Corticosteroids, moderately p
Page 137 and 138:
D08AD Boric acid products 136 Weak
Page 139 and 140:
D10AB Preparations containing sulfu
Page 141 and 142:
D11AX Other dermatologicals 140 Thi
Page 143 and 144:
G GENITO URINARY SYSTEM AND SEX HOR
Page 145 and 146:
G02 OTHER GYNECOLOGICALS 144 Analge
Page 147 and 148:
146 Lisuride tablets in high streng
Page 149 and 150:
G03AD Emergency contraceptives 148
Page 151 and 152:
G03CX Other estrogens 150 Tibolone
Page 153 and 154:
152 package which is intended for o
Page 155 and 156:
G04BC Urinary concrement solvents 1
Page 158 and 159:
H SYSTEMIC HORMONAL PREPARATIONS, E
Page 160 and 161:
The DDDs are based on the treatment
Page 162 and 163:
H02A CORTICOSTEROIDS FOR SYSTEMIC U
Page 164 and 165:
H04 PANCREATIC HORMONES H04A GLYCOG
Page 166 and 167:
J ANTIINFECTIVES FOR SYSTEMIC USE J
Page 168 and 169:
J01 ANTIBACTERIALS FOR SYSTEMIC USE
Page 170 and 171:
inhibitor are classified at a separ
Page 172 and 173:
J01EA Trimethoprim and derivatives
Page 174 and 175:
J01MA Fluoroquinolones Flumequine i
Page 176 and 177: The parenteral DDD for fosfomycin i
Page 178 and 179: J04B DRUGS FOR TREATMENT OF LEPRA J
Page 180 and 181: The DDD of oseltamivir is based on
Page 182 and 183: 5th level, while other monovalent v
Page 184: J07BJ Rubella vaccines Combinations
Page 187 and 188: L ANTINEOPLASTIC AND IMMUNOMODULATI
Page 189 and 190: L01X OTHER ANTINEOPLASTIC AGENTS 18
Page 191 and 192: L03AA Colony stimulating factors L0
Page 194 and 195: M MUSCULO-SKELETAL SYSTEM M01 ANTII
Page 196 and 197: Combinations with drugs classified
Page 198 and 199: M01CA Quinolines The DDDs are based
Page 200 and 201: M03AC Other quaternary ammonium com
Page 202 and 203: M05 DRUGS FOR TREATMENT OF BONE DIS
Page 204 and 205: N NERVOUS SYSTEM N01 ANESTHETICS A
Page 206 and 207: N01AX Other general anesthetics Thi
Page 208 and 209: N02A OPIOIDS This group comprises s
Page 210 and 211: N02AG Opioids in combination with a
Page 212 and 213: Lysine acetylsalicylate is classifi
Page 214 and 215: The DDDs for the substances in this
Page 216 and 217: The DDD for the combination of levo
Page 218 and 219: N05AN Lithium The DDD is based on t
Page 220 and 221: The DDDs are based on use of the dr
Page 222 and 223: N06AF Monoamine oxidase inhibitors,
Page 224 and 225: N07B DRUGS USED IN ADDICTIVE DISORD
Page 228 and 229: The DDDs in this group are based on
Page 230 and 231: P01C AGENTS AGAINST LEISHMANIASIS A
Page 232 and 233: The DDD for diethylcarbamazine is b
Page 234 and 235: R RESPIRATORY SYSTEM R01 NASAL PREP
Page 236 and 237: The DDDs are based on the treatment
Page 238 and 239: Antibiotics for systemic use, see J
Page 240 and 241: The DDDs for combination products a
Page 242 and 243: R03DA Xanthines A number of prepara
Page 244 and 245: R05D COUGH SUPPRESSANTS, EXCL. COMB
Page 246 and 247: The group is subdivided according t
Page 248 and 249: S SENSORY ORGANS S01 OPHTHALMOLOGIC
Page 250 and 251: S01AX Other antiinfectives This gro
Page 252 and 253: S01ED Beta blocking agents Combinat
Page 254 and 255: Hypromellose is classified in this
Page 256 and 257: S02D OTHER OTOLOGICALS This group c
Page 258 and 259: V VARIOUS V01 ALLERGENS A Allergens
Page 260 and 261: V VARIOUS This group comprises many
Page 262 and 263: The DDDs for calcium folinate, calc
Page 264 and 265: V06 GENERAL NUTRIENTS This group co
Page 266 and 267: V07AS Stomi equipment V07AT Cosmeti
Page 268 and 269: ( 99m Tc) exametazime labelled cell
Page 270 and 271: classified according to such indica
Page 272 and 273: V10 THERAPEUTIC RADIOPHARMACEUTICAL
Page 274 and 275: List of terms: AC-system Anatomical
Page 276:
Plain preparation Preparations cont
Page 280 and 281:
Requested by: Name: Company: Addres
Page 282:
ANNEX II
Page 285 and 286:
Payment details ORDER FORM - ATC/DD
show all

Guidelines for ATC classification and DDD assignment - WHOCC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?